The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis

Abstract Background There is an unmet need for treatment of long-term symptoms following COVID-19. Remdesivir is currently the only antiviral approved by the European Medicines Agency for hospitalised patients. Here, we report on the effect of remdesivir in addition to standard of care on long-term...

Full description

Saved in:
Bibliographic Details
Main Authors: Thale D. J. Hovdun Patrick-Brown, Andreas Barratt-Due, Marius Trøseid, Anne Ma Dyrhol-Riise, Katerina Nezvalova-Henriksen, Trine Kåsine, Pål Aukrust, Inge C. Olsen, NOR Solidarity consortium
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00650-4
Tags: Add Tag
No Tags, Be the first to tag this record!